<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium oxybate (gamma hydroxybutyrate): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium oxybate (gamma hydroxybutyrate): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sodium oxybate (gamma hydroxybutyrate): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8817" href="/d/html/8817.html" rel="external">see "Sodium oxybate (gamma hydroxybutyrate): Drug information"</a> and <a class="drug drug_patient" data-topicid="11049" href="/d/html/11049.html" rel="external">see "Sodium oxybate (gamma hydroxybutyrate): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709423"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Central nervous system depression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sodium oxybate is a CNS depressant. In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in adult patients treated with sodium oxybate. Many patients who received sodium oxybate during clinical trials in narcolepsy were receiving CNS stimulants.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Abuse and misuse:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sodium oxybate is the sodium salt of gamma hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Restricted access:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because of the risks of CNS depression, abuse, and misuse, sodium oxybate is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Lumryz REMS or Xywav and Xyrem REMS.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F175564"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lumryz;</li>
<li>Xyrem</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867030"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Xyrem</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1036192"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Central Nervous System Depressant</span></li></ul></div>
<div class="block dop drugH1Div" id="F52102296"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8711007-1017-4637-a97c-593e06f5423f">Narcolepsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy (excessive daytime sleepiness/cataplexy): Note:</b> Nightly, 2 doses are administered; some patients may require unequal doses to achieve optimal response. Dosing is present in <b>mg</b>/kg and grams; use precaution.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate-release oral solution (Xyrem):</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;20 kg: Oral: Limited data available: Initial: 60 to 90 <b>mg</b>/kg/night (total dose) in 2 divided doses; the first dose administered at bedtime after the patient is in bed, then 2.5 to 4 hours later, administer the second dose; titrate every 1 to 2 weeks until efficacy or development of intolerable side effects. Reported maximum daily dose: 180 <b>mg</b>/kg/night (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21102987','lexi-content-ref-29512449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21102987','lexi-content-ref-29512449'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">20 to &lt;30 kg: Oral: Initial: ≤1 g at bedtime after the patient is in bed, then 2.5 to 4 hours later, administer second dose of ≤1 g. After 1 week, titrate dose based on efficacy and tolerability at weekly intervals; increase dose in ≤0.5 g/dose (≤1 g/night) increments per week; maximum single dose: 3 g/dose; maximum daily dose: 6 g/night.</p>
<p style="text-indent:-2em;margin-left:8em;">30 to &lt;45 kg: Oral: Initial: ≤1.5 g at bedtime after the patient is in bed, then 2.5 to 4 hours later, administer second dose of ≤1.5 g. After 1 week, titrate dose based on efficacy and tolerability at weekly intervals; increase dose in ≤0.5 g/dose (≤1 g/night) increments per week; maximum single dose: 3.75 g/dose; maximum daily dose: 7.5 g/ night.</p>
<p style="text-indent:-2em;margin-left:8em;">≥45 kg: Oral: Initial: ≤2.25 g at bedtime after the patient is in bed, then 2.5 to 4 hours later, administer second dose of ≤2.25 g . After 1 week, titrate dose based on efficacy and tolerability at weekly intervals; increase dose in ≤0.75 g/dose (1.5 g/night) increments per week; maximum single dose: 4.5 g/dose; maximum daily dose: 9 g/night.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F54686376"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F54686377"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥7 years and Adolescents: Immediate-release oral solution (Xyrem): Reduce initial total nightly dose by 50% and administer in 2 divided doses.</p></div>
<div class="block doa drugH1Div" id="F175566"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8817" href="/d/html/8817.html" rel="external">see "Sodium oxybate (gamma hydroxybutyrate): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8711007-1017-4637-a97c-593e06f5423f">Narcolepsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">ER suspension (Lumryz): 4.5 g as a single dose at bedtime. May increase nightly dose by 1.5 g at weekly intervals based on efficacy and tolerability; recommended dosage range: 6 to 9 g once daily at night. Maximum dose: 9 g/night.</p>
<p style="text-indent:-2em;margin-left:4em;">IR solution (Xyrem): Initial: 2.25 g at bedtime after the patient is in bed, and 2.25 g administered 2.5 to 4 hours later (4.5 g/night). May increase nightly dose by 1.5 g (0.75 g at bedtime and 0.75 g administered 2.5 to 4 hours later) at weekly intervals based on efficacy and tolerability; usual effective dosage range: 6 to 9 g per night. Maximum dose: 9 g/night.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed second dose:</i> Skip dose and resume usual dosing schedule the next day. Do not administer 2 doses at the same time.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching from IR solution (Xyrem) to ER suspension (Lumryz): </b>Administer the nearest total equivalent dose in grams once per night.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991436"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988730"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">ER suspension (Lumryz): Do not use as initial therapy in patients with hepatic impairment; patients who have been titrated to a maintenance dose on IR solution may be switched to the ER suspension if the appropriate dosage strength is available.</p>
<p style="text-indent:-2em;margin-left:2em;">IR solution (Xyrem): Reduce initial dose(s) by 50%.</p></div>
<div class="block adr drugH1Div" id="F175532"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (children and adolescents: 13%; adults: 1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (children, adolescents, and adults: 6% to 20%), vomiting (children, adolescents, and adults: 2% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence (children and adolescents: 19%; adults: 2% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion (2% to 17%), dizziness (children, adolescents, and adults: 4% to 15%), headache (children and adolescents: 17%; adults: 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (children and adolescents: 9%; adults: 3% to 4%), diarrhea (3% to 4%), upper abdominal pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (2% to 8%), depression (children, adolescents, adults: 1% to 7%), disorientation (2% to 3%), disturbance in attention (1% to 4%), drowsiness (2% to 8%), intoxicated feeling (3%), irritability (3%), pain (3%), paresthesia (2% to 3%), severe central nervous system depression (2%), somnambulism (children, adolescents, and adults: 1% to 6%), tremor (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Suicidal ideation (children, adolescents, adults), suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all populations):</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Oxygen desaturation</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium, emotional disturbance (including obsessive thoughts), obtundation</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory depression</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fluid retention</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nocturia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation, drug abuse, falling, hallucination, hangover effect, memory impairment, panic attack, paranoid ideation, parasomnias (sleep driving, sleep eating) (Wallace 2011), psychosis (including acute psychosis) (Langford 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sleep apnea (Hartley 2011)</p></div>
<div class="block coi drugH1Div" id="F175545"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use with alcohol or sedative-hypnotic agents; succinic semialdehyde dehydrogenase deficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to sodium oxybate or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F175530"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Behavioral and psychiatric effects: Use has been associated with aggression, agitation, anxiety, confusion, depression, paranoia, psychosis, suicidality, and hallucinations; use caution in patients with history of depression and/or suicide attempt.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: Sodium oxybate may impair physical or mental abilities. Patients must be instructed not to engage in hazardous activities requiring mental alertness or motor coordination for at least 6 hours after taking sodium oxybate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parasomnias: Parasomnias, including sleepwalking, may occur with use. Evaluate episodes of sleepwalking and implement appropriate interventions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory depression: <b>[US Boxed Warning]: In clinical trials at recommended doses, obtundation and clinically significant respiratory depression occurred in sodium oxybate-treated adult patients. Many of the patients who received sodium oxybate during clinical trials in narcolepsy were receiving CNS stimulants.</b> Use with caution in patients with compromised respiratory function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart failure or hypertension; contains significant amounts of sodium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment due to significant amounts of sodium in the product.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related breathing disorders: Sleep-related breathing disorders (eg, sleep apnea) may occur during therapy; may be more common in patients that are obese, male, postmenopausal (not on hormone-replacement therapy), or narcoleptic. In pediatric patients, central sleep apnea and oxygen desaturation has been reported.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Although limited data exists, headache was observed at a higher incidence in older adults ≥65 years of age compared to younger adults. Older adults may also be at increased risk for other CNS effects; use with caution and monitor cognitive/motor function closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: <b>[US Boxed Warning]: Sodium oxybate (the sodium salt of gamma hydroxybutyrate [GHB]) is a CNS depressant controlled substance with abuse potential. Seizures, respiratory depression, decreases in level of consciousness, coma, and death have been reported when GHB, either alone or in combination with other CNS depressants, has been abused.</b> Health care providers should be alert to problems of abuse, misuse, and diversion. Patients should be evaluated for a history of drug abuse and should be monitored for signs of misuse, abuse, and substance use disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium: Contains high sodium content: Use with caution in patients sensitive to high sodium intake (eg, renal impairment, heart failure, hypertension).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance/withdrawal: Tolerance to sodium oxybate, or withdrawal following its discontinuation, has not been clearly defined in controlled clinical trials, but has been reported at larger doses used for illicit purposes.</p></div>
<div class="block dosfc drugH1Div" id="F54686378"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Sodium content for various doses:</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Total nightly sodium oxybate dose</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Sodium content</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">3 g</p></td>
<td align="center">
<p style="text-indent:0em;">550 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4.5 g</p></td>
<td align="center">
<p style="text-indent:0em;">820 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">6 g</p></td>
<td align="center">
<p style="text-indent:0em;">1,100 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">7.5 g</p></td>
<td align="center">
<p style="text-indent:0em;">1,400 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">9 g</p></td>
<td align="center">
<p style="text-indent:0em;">1,640 mg</p></td></tr></tbody></table></div>
<div class="block foc drugH1Div" id="F175540"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lumryz: 4.5 g (7 ea, 30 ea); 6 g (7 ea, 30 ea); 7.5 g (7 ea, 30 ea); 9 g (7 ea, 30 ea) [contains carrageenan]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xyrem: 500 mg/mL (180 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/mL (180 mL)</p></div>
<div class="block geq drugH1Div" id="F175527"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323168"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Lumryz Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.5 g (per each): $366.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 g (per each): $488.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 g (per each): $611.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9 g (per each): $733.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sodium Oxybate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/mL (per mL): $40.13 - $41.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xyrem Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/mL (per mL): $44.27</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867031"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xyrem: 500 mg/mL (180 mL)</p></div>
<div class="block adip drugH1Div" id="F53566853"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Sodium oxybate is a known substance of abuse. When used illegally, it has been referred to as a "date-rape drug." As part of the FDA approval for prescription use, all patients and prescribers must be enrolled in a program designed to restrict its distribution and to provide postmarketing evaluations (see "REMS Program" and "Prescribing Access and Restrictions"). Detailed instructions for the use of sodium oxybate should be provided to the patient and health care provider prior to dispensing the first dose.</p></div>
<div class="block csi drugH1Div" id="F175588"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-I (illicit use); C-III (medical use)</p></div>
<div class="block accres drugH1Div" id="F11234332"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:-2em;margin-left:2em;">Access to sodium oxybate is restricted under the Lumryz REMS or the Xywav and Xyrem REMS. The programs are intended to ensure health care providers are specially certified and is dispensed only by specially certified pharmacies. Patients must also enroll in the program and have documentation of safe use conditions. Further information regarding the Lumryz REMS program may be obtained at 1-877-453-1029 or for the Xywav and Xyrem REMS at 1-866-997-3688 or http://www.xywavxyremrems.com.</p>
<p style="text-indent:-2em;margin-left:2em;">In Canada, access to sodium oxybate is restricted under the Xyrem Success Program. The program is intended to educate prescribers, pharmacists, and patients on the safe use, storage, and handling of the drug, to maintain a registry of trained physicians, pharmacies, and patients, and to limit distribution through a single wholesaler to pharmacies on an as-needed basis after a prescription is received by the pharmacy. Initial dispensing of prescriptions should occur only after the prescriber, pharmacist, and patient have received and read the educational materials. Further information regarding the program may be obtained at 1-866-599-7365.</p></div>
<div class="block admp drugH1Div" id="F52612906"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Immediate-release oral solution (Xyrem): Administer on an empty stomach (at least 2 hours after eating); administration at similar times each night is preferred. Each nightly dose should be administered while patient is sitting up in bed; then patient should lie down and remain in bed; sleep generally occurs within 5 to 15 minutes (generally abruptly without patient feeling drowsy). Both doses should be prepared prior to bedtime. The first dose is administered at bedtime and the second dose 2.5 to 4 hours later; an alarm clock may need to be set for the second dose. For patients who sleep &gt;8 hours per night the first dose may be administered at bedtime or after an initial period of sleep. After use, rinse containers with water.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If the second dose is missed, skip that dose and resume therapy the next night; do not administer both doses at the same time. Diluted doses that are not used should be properly and promptly disposed.</p></div>
<div class="block adm drugH1Div" id="F175542"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer on an empty stomach, ≥2 hours after eating. Administer while patient is in bed; patient should lie down immediately after dose and remain in bed.</p>
<p style="text-indent:-2em;margin-left:4em;">ER suspension (Lumryz): Administer at bedtime. Prepare dose prior to bedtime. Prior to ingestion, suspend dose in ~<sup>1</sup>/<sub>3</sub> cup (~80 mL) of water in provided mixing cup; do not use hot water. Administer within 30 minutes of mixing.</p>
<p style="text-indent:-2em;margin-left:4em;">IR solution (Xyrem): Administer first dose at bedtime. Administer second nightly dose 2.5 to 4 hours after the first dose; an alarm clock may need to be set for the second dose. Prepare both doses prior to bedtime. Prior to ingestion, dilute each dose with ~<sup>1</sup>/<sub>4</sub> cup (60 mL) water in provided empty pharmacy containers.</p></div>
<div class="block sts drugH1Div" id="F175559"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">ER suspension (Lumryz): Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Diluted suspension should be consumed within 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">IR solution (Xyrem): Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86 °F). Store in the original bottle. Dispense in tight containers. Diluted solution should be consumed within 24 hours.</p></div>
<div class="block meg drugH1Div" id="F7874990"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021196s042lbl.pdf%23page%3D26&amp;token=Y2%2FVvG%2BS%2FAhL6DC1j%2BPwjCbtM0SGN%2FfrAnW3uVtB8K%2BDYKJA3gRa7dqrDus1XxxkcPoQEkZDe5VT7RNqnLsio62mYEKPDCiouAIj34dpTP%2BOjAjQBVAOtz%2FP6kvu0qxA&amp;TOPIC_ID=129140" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021196s042lbl.pdf#page=26</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53567063"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy (Immediate-release oral solution [Xyrem]: FDA approved in ages ≥7 years and adults; extended-release oral suspension [Lumryz]: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F55863356"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Sodium oxybate may be confused with oxybate salts (calcium, magnesium, potassium, and sodium).</p>
<p style="text-indent:-2em;margin-left:4em;">Xyrem may be confused with Xywav.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300063"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F175534"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of Oxybate Salt Products. Alcohol (Ethyl) may increase the serum concentration of Oxybate Salt Products. Specifically, alcohol may increase concentrations of the sodium oxybate extended release suspension.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzodiazepines: May enhance the CNS depressant effect of Oxybate Salt Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypnotics (Nonbenzodiazepine): May enhance the CNS depressant effect of Oxybate Salt Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Oxybate Salt Products may enhance the CNS depressant effect of Rilmenidine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Sodium Oxybate. Management: Decrease the dose of sodium oxybate immediate release oral solution by at least 20% when initiating therapy with valproate products. No dose adjustment recommended when sodium oxybate extended release suspension is combined with valproate products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F175561"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration immediately after a high-fat meal delays absorption and decreases peak serum gamma-hydroxybutyrate level. Management: Administer on an empty stomach ≥2 hours after eating.</p></div>
<div class="block dic drugH1Div" id="F175549"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Contains a high sodium content; limit dietary intake of sodium.</p></div>
<div class="block pri drugH1Div" id="F175548"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">The injection formulation, when used as an anesthetic during labor and delivery, was shown to cross the placenta; a slight decrease in Apgar scores due to sleepiness in the neonate was observed.</p></div>
<div class="block mopp drugH1Div" id="F54686380"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of depression or suicidality; emergence of anxiety, confusion, thought disorders, or behavior abnormalities; drug abuse, misuse, and substance use disorder.</p></div>
<div class="block pha drugH1Div" id="F175529"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The active moiety of sodium oxybate is gamma-hydroxybutyrate (GHB). The therapeutic effects of GHB, a metabolite of gamma aminobutyric acid (GABA), are hypothesized to be mediated by GABA<sub>B</sub> receptor activity at noradrenergic, dopaminergic, and thalamocortical neurons.</p></div>
<div class="block phk drugH1Div" id="F175544"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pharmacokinetic parameters in pediatric patients 7 to 17 years were reported as being similar to adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset: Rapid (≤5 to 15 minutes).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid; high-fat meals delay absorption (average T<sub>max</sub> increased 1 hour [extended release] and 1.25 hours [immediate release]) and reduce the C<sub>max</sub> by a mean 33% (extended release), 59% (immediate release) and AUC by 14% (extended release), 37% (immediate release).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 190 to 384 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;1%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily via the Krebs cycle to form water and carbon dioxide; secondarily via beta oxidation; significant first-pass effect; no active metabolites; metabolic pathways are saturable.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~88%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 30 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Extended release: 90 minutes; Immediate release: 30 to 75 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily pulmonary (as carbon dioxide); urine (&lt;5% as unchanged drug); feces (negligible).</p></div>
<div class="block phksp drugH1Div" id="F51221392"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC is doubled, elimination half-life is longer, and oral clearance is reduced in cirrhotic patients (Child-Pugh class A and C).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F175550"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Xyrem</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Oxybate accord | Xyrem</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Xyrem</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sodium oxybate kalceks | Xyrem</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Xyrem</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sodium oxybate kalceks</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Anartex | Oxibato de sodio aristo | Oxibato de sodio normon | Sodium oxybate sala</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Natriumoxibat kalceks | Natriumoxibat reig jofre</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Oxybate de sodium kalceks</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Sodium oxybate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Xyrem</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Sodium oxybate | Xyrem</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alcover | Sodio Oxibato Accord | Sodio oxibato kalceks</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sodium oxybate kalceks</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Natriumoxybaat accord | Natriumoxybaat aristo | Sodium oxybate</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Natriumoksybat kalceks | Xyrem</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Xyrem</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sodium oxybate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Xyrem</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Xyrem</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Arixobat | Natriumoxibat kalceks | Natriumoxibat reig jofre | Xyrem</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sodium oxybate kalceks | Xyrem</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Xyrem</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21102987">
<a name="21102987"></a>Aran A, Einen M, Lin L, Plazzi G, Nishino S, Mignot E. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. <i>Sleep</i>. 2010;33(11):1457-1464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-oxybate-gamma-hydroxybutyrate-pediatric-drug-information/abstract-text/21102987/pubmed" id="21102987" target="_blank">21102987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28668666">
<a name="28668666"></a>Barker EC, Puchowicz M, Letterio J, Higgins K, Sharkey KM. GHB levels in breast milk of women with narcolepsy with cataplexy treated with sodium oxybate. <i>Sleep Med</i>. 2017;36:172-177. doi: 10.1016/j.sleep.2017.05.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-oxybate-gamma-hydroxybutyrate-pediatric-drug-information/abstract-text/28668666/pubmed" id="28668666" target="_blank">28668666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26968013">
<a name="26968013"></a>Busardò FP, Bertol E, Mannocchi G, et al. Determination of GHB levels in breast milk and correlation with blood concentrations. <i>Forensic Sci Int</i>. 2016;265:172-181. doi: 10.1016/j.forsciint.2016.02.020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-oxybate-gamma-hydroxybutyrate-pediatric-drug-information/abstract-text/26968013/pubmed" id="26968013" target="_blank">26968013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22171208">
<a name="22171208"></a>Hartley S, Quera-Salva MA, Machou M. Sodium oxybate and sleep apnea: a clinical case. <i>J Clin Sleep Med</i>. 2011;7(6):667-668. doi:10.5664/jcsm.1480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-oxybate-gamma-hydroxybutyrate-pediatric-drug-information/abstract-text/22171208/pubmed" id="22171208" target="_blank">22171208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22171207">
<a name="22171207"></a>Langford J, Gross WL. Psychosis in the context of sodium oxybate therapy. <i>J Clin Sleep Med</i>. 2011;7(6):665-666. doi:10.5664/jcsm.1478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-oxybate-gamma-hydroxybutyrate-pediatric-drug-information/abstract-text/22171207/pubmed" id="22171207" target="_blank">22171207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lumryz.1">
<a name="Lumryz.1"></a>Lumryz (sodium oxybate) [prescribing information]. Chesterfield, MO: Avadel CNS Pharmaceuticals, LLC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29512449">
<a name="29512449"></a>Moresco M, Pizza F, Antelmi E, Plazzi G. Sodium oxybate treatment in pediatric type 1 narcolepsy. <i>Curr Drug Metab</i>. 2018;19(13):1073-1079.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-oxybate-gamma-hydroxybutyrate-pediatric-drug-information/abstract-text/29512449/pubmed" id="29512449" target="_blank">29512449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18246980">
<a name="18246980"></a>Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. <i>Sleep.</i> 2007;30(12):1705-17711.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-oxybate-gamma-hydroxybutyrate-pediatric-drug-information/abstract-text/18246980/pubmed" id="18246980" target="_blank">18246980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21677903">
<a name="21677903"></a>Wallace DM, Maze T, Shafazand S. Sodium oxybate-induced sleep driving and sleep-related eating disorder. <i>J Clin Sleep Med</i>. 2011;7(3):310-311. doi:10.5664/JCSM.1082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-oxybate-gamma-hydroxybutyrate-pediatric-drug-information/abstract-text/21677903/pubmed" id="21677903" target="_blank">21677903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xyrem.1">
<a name="Xyrem.1"></a>Xyrem (sodium oxybate) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; April 2023.</div>
</li>
<li>
<div class="reference">
                  Xyrem (sodium oxybate) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies; September 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 129140 Version 93.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
